EUVIMEDEUVIMED entdecken
Crossref

Carbonic anhydrase inhibition by antiviral drugs in vitro and in silico

Cüneyt Türkeş iD

Journal of Molecular Recognition · 2023-12 · 36 (12)

DOI: 10.1002/jmr.3063 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Molecular Recognition, online erschienen am 08.10.2023. Verfasst von Cüneyt Türkeş. Beteiligte Einrichtung: Department of Biochemistry, Faculty of Pharmacy, Erzincan Binali Yıldırım University, Erzincan, Turkey. Hauptthemen laut MEDLINE: Carbonic Anhydrases. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 77 Literaturangaben. Gefördert von: Research Fund of Erzincan Binali Yıldırım University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enzyme inhibition is a commonly utilized method for controlling enzymatic activity in various physiologically relevant biological systems. Herein, the selected five active antiviral drugs, abacavir, emtricitabine, lamivudine, ribavirin, and ritonavir, were assayed as inhibitors of two human isoforms of the metalloenzyme carbonic anhydrase ( h CA, EC 4.2.1.1) involved in various physiological/pathological conditions. For this aim, in vitro and in silico studies were performed to gain insights into the plausible binding interactions and affinities for the antiviral drugs within h CA I and II isoforms' active sites. The h CA I, an isoform involved in some pathological conditions such as retinal or cerebral edema, was moderately inhibited by these five drugs at micromolar concentrations with K I s spanning from 0.49 ± 0.05 to 3.51 ± 0.37 μM compared with the reference drug acetazolamide (AAZ, K I of 0.19 ± 0.01 μM). Moreover, h CA II, a promising target for edema, glaucoma, epilepsy, and altitude sickness, was a reasonably inhibited isoform by these agents, with K I s in the range of 0.64 ± 0.08–5.80 ± 0.64 μM compared with AAZ ( K I of 0.17 ± 0.01 μM). Both in vitro and in silico results demonstrated significant interactions between these five drugs and h CAs and that they can support therapeutic targets against the above‐mentioned pathological conditions. Additionally, the results obtained will help optimize the clinical dosage regimens of these drugs and avoid drug–drug interactions unexpectedly when used in combination with other agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carbonic AnhydrasesHumansMolecular StructureStructure-Activity RelationshipAntiviral AgentsCarbonic Anhydrase InhibitorsSulfonamidesProtein Isoforms

Stichwörter der Autor:innen

antiviral agentscarbonic anhydraseinhibitormetalloenzymemolecular docking

Substanzen

Carbonic AnhydrasesAntiviral AgentsCarbonic Anhydrase InhibitorsSulfonamidesProtein Isoforms

Autor:innen und Institutionen

  • Department of Biochemistry, Faculty of Pharmacy, Erzincan Binali Yıldırım University, Erzincan, Turkey.

ORCID-Profile: Cüneyt Türkeş

Förderung

  • Research Fund of Erzincan Binali Yıldırım University

Zitieren

APA

Türkeş, C. (2023). Carbonic anhydrase inhibition by antiviral drugs in vitro and in silico. Journal of Molecular Recognition, 36(12). https://doi.org/10.1002/jmr.3063

Vancouver

Türkeş C. Carbonic anhydrase inhibition by antiviral drugs in vitro and in silico. Journal of Molecular Recognition. 2023;36(12). doi:10.1002/jmr.3063

BibTeX
@article{Trke2023,
  author = {Türkeş, Cüneyt},
  title = {Carbonic anhydrase inhibition by antiviral drugs in vitro and in silico},
  journal = {Journal of Molecular Recognition},
  year = {2023},
  volume = {36},
  number = {12},
  doi = {10.1002/jmr.3063}
}
Kostenlos starten →